Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.
You may also be interested in...
Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.
Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.